ArticleThe Journal of clinical investigation1984
Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.
Article in The Journal of clinical investigation, 1984. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 250 citations in OpenAlex.
- Mapping organ-associated autoantigenic landscapes in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- The Diagnostic Value of Contrast-Enhanced Vessel Wall MRI for Diagnosing Neuropsychiatric Systemic Lupus Erythematosus.Journal of magnetic resonance imaging : JMRI · 2025Article
- Antibodies and Immunity During Kawasaki Disease.Frontiers in cardiovascular medicine · 2020Review
- Immune Complexes Impaired Glomerular Endothelial Cell Functions in Lupus Nephritis.International journal of molecular sciences · 2019Article
- B Cells and Antibodies in Kawasaki Disease.International journal of molecular sciences · 2019Review
- Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.Hypertension (Dallas, Tex. : 1979) · 2018Article
- Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cells.Molecular immunology · 2013Article
- Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2012Article
- Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown.Clinical & developmental immunology · 2012Review
- Antiendothelial cell antibodies in vasculitis and connective tissue disease.Annals of the rheumatic diseases · 2006Review
- Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis.Clinical and experimental immunology · 2000Article
- Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity.Clinical and experimental immunology · 1999Article
- Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.Clinical and experimental immunology · 1999Article
- The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis.The Journal of clinical investigation · 1998Article
- Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schönlein purpura.Archives of disease in childhood · 1998Article
- Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies.Clinical and diagnostic laboratory immunology · 1997Article
- Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjögren's syndrome.Annals of the rheumatic diseases · 1997Article
- Antiendothelial cell antibodies (AECA) in systemic lupus erythematosus (SLE).Clinical reviews in allergy & immunology · 1997Review
- Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies.Annals of the rheumatic diseases · 1996Article
- Complement-mediated regulation of tissue factor activity in endothelium.The Journal of experimental medicine · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Vasculitis in systemic lupus erythematosus (SLE) is associated with the deposition of IgG and complement in blood vessel walls. However, it is not known whether immune injury to endothelial cells is a part of this process. Therefore, we used a solid phase radioimmunoassay to study the ability of IgG from normal human sera and sera from patients with SLE to bind to endothelial cells. In this assay, cultured human umbilical venous endothelial cells were sequentially incubated with normal or SLE sera, goat anti-human IgG, and 125I-labeled staphylococcal protein A (*SPA). After exposure to normal sera, 2.5 +/- 0.5% (mean +/- SD) of the added *SPA bound to the cells, whereas after exposure to SLE sera 13.8 +/- 7.6% of the added *SPA bound to these cells. This difference in binding was highly significant (P less than 0.001). Binding was partially reduced when SLE sera were preincubated with B-lymphocytes or monocytes, but not after exposure to erythrocytes, platelets, or T lymphocytes. Incubation of endothelial cells with the 7S fraction of SLE sera or with the F(ab')2 fragment of SLE-IgG resulted in the deposition of greater than 80% as much IgG as was deposited on endothelial cells by whole serum. However, since higher molecular weight fractions (greater than 7S) of SLE sera were also active, we tested the capacity of endothelial cells to bind IgG complexes. Endothelial cells bound heat-aggregated IgG (HA-IgG) in a saturable manner at one log concentration below the binding of normal monomeric IgG. Binding of HA-IgG to endothelial cells was markedly enhanced by preincubation with a serum source of complement. Both HA-IgG and SLE-IgG also bound to freshly obtained endothelial cells in suspension, as detected by automated fluorescence flow cytometry. Binding of SLE-IgG and HA-IgG to endothelium initiated complement activation, deposition of the third component of complement, and disruption of the monolayer. In addition, SLE-IgG and HA-IgG caused endothelial cells to secrete prostacyclin and caused the adherence of platelets, confirmed by scanning electron microscopy. These studies demonstrate that IgG anti-endothelial antibodies are present in the sera of patients with active SLE. These sera may also contain IgG complexes that are capable of binding to endothelial cells. The association of IgG and complement with endothelial cells may initiate vascular injury in SLE and other human disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.